PriceTargets.com logo

INmune Bio - INMB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 354.55%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.40 As of 12/20/2024 06:16 PM ET
▼ -0.02 (-0.45%)

This chart shows the closing price for INMB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New INmune Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INMB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INMB

Analyst Price Target is $20.00
▲ +354.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for INmune Bio in the last 3 months. The average price target is $20.00, with a high forecast of $22.00 and a low forecast of $18.00. The average price target represents a 354.55% upside from the last price of $4.40.

This chart shows the closing price for INMB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in INmune Bio. This rating has held steady since April 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/21/2024Alliance Global PartnersInitiated CoverageBuy$20.00
9/27/2024Raymond JamesInitiated CoverageOutperform$18.00
8/22/2024ScotiabankInitiated CoverageSector Outperform$22.00
5/31/2023Robert W. BairdInitiated CoverageOutperform$16.00
5/24/2022BTIG ResearchLower TargetBuy$31.00 ➝ $14.00
5/24/2022B. RileyDowngradeBuy ➝ Neutral$14.00 ➝ $7.00
5/11/2022B. RileyReiterated RatingBuy
5/6/2022Maxim GroupInitiated CoverageBuy$22.00
3/4/2022Maxim GroupReiterated RatingBuy$22.00
1/24/2022B. RileyLower TargetBuy$32.00 ➝ $20.00
9/7/2021B. RileyBoost TargetBuy$26.00 ➝ $32.00
7/14/2021B. RileyReiterated RatingBuy$29.00 ➝ $34.00
7/7/2021Maxim GroupBoost TargetBuy$32.00 ➝ $42.00
4/27/2021B. RileyInitiated CoverageBuy$29.00
4/21/2021B. RileyReiterated RatingBuy$29.00
2/9/2021Maxim GroupReiterated RatingBuy$13.00
1/22/2021Maxim GroupBoost TargetPositive ➝ Buy$16.00 ➝ $32.00
11/9/2020HC WainwrightLower TargetBuy$20.00 ➝ $15.00
9/1/2020BTIG ResearchInitiated CoverageBuy$23.00
8/6/2020HC WainwrightReiterated RatingBuy$20.00
7/15/2020HC WainwrightBoost TargetBuy$7.00 ➝ $20.00
7/14/2020Roth CapitalBoost TargetReduce ➝ Buy$13.00 ➝ $26.00
5/16/2020Maxim GroupInitiated CoverageBuy$13.00
5/15/2020HC WainwrightReiterated RatingBuy$7.00 ➝ $8.00
4/22/2020Maxim GroupReiterated RatingBuy$13.00
3/13/2020Maxim GroupReiterated RatingBuy$13.00
3/12/2020HC WainwrightLower TargetBuy$11.00 ➝ $8.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
INmune Bio logo
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Read More

Today's Range

Now: $4.40
Low: $4.32
High: $4.60

50 Day Range

MA: $5.27
Low: $4.40
High: $6.43

52 Week Range

Now: $4.40
Low: $4.32
High: $14.74

Volume

402,081 shs

Average Volume

169,869 shs

Market Capitalization

$97.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of INmune Bio?

The following Wall Street sell-side analysts have issued reports on INmune Bio in the last twelve months: Alliance Global Partners, Raymond James, and Scotiabank.
View the latest analyst ratings for INMB.

What is the current price target for INmune Bio?

0 Wall Street analysts have set twelve-month price targets for INmune Bio in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 354.5%. Scotiabank has the highest price target set, predicting INMB will reach $22.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $18.00 for INmune Bio in the next year.
View the latest price targets for INMB.

What is the current consensus analyst rating for INmune Bio?

INmune Bio currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INMB will outperform the market and that investors should add to their positions of INmune Bio.
View the latest ratings for INMB.

What other companies compete with INmune Bio?

Other companies that are similar to INmune Bio include Korro Bio, SIGA Technologies, Corvus Pharmaceuticals, KalVista Pharmaceuticals and Aura Biosciences. Learn More about companies similar to INmune Bio.

How do I contact INmune Bio's investor relations team?

INmune Bio's physical mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company's listed phone number is (858) 964-3720 and its investor relations email address is [email protected]. The official website for INmune Bio is www.inmunebio.com. Learn More about contacing INmune Bio investor relations.